A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

NCT02483247 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: BBI503
DRUG: Capecitabine
DRUG: Doxorubicin
DRUG: Nivolumab
DRUG: Pembrolizumab
DRUG: Paclitaxel
DRUG: Sunitinib

Sponsor

Sumitomo Pharma America, Inc.